[1] |
Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35 (12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
|
[2] |
European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398. DOI: 10.1016/j.jhep.2017.03.021.
|
[3] |
MARCELLIN P, HEATHCOTE EJ, BUTI M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B[J]. N Engl J Med, 2008, 359(23): 2442-2455. DOI: 10.1056/NEJMoa0802878.
|
[4] |
GAO ZL. Hot and difficult points of functional cure (clinical cure) of chronic hepatitis B[J]. Mod Digest Interv, 2019, 24(9): 949-951. DOI: 10.3969/j.issn.1672-2159.2019.09.001.
高志良. 慢性乙型肝炎功能性治愈(临床治愈)的热点和难点[J]. 现代消化及介入诊疗, 2019, 24(9): 949-951. DOI: 10.3969/j.issn.1672-2159.2019.09.001.
|
[5] |
Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B: A 2015 update[J]. J Clin Hepatol, 2015, 31(12): 1941-1960. DOI: 10.3969/j.issn.1001-5256.2015.12.002.
中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年更新版)[J]. 临床肝胆病杂志, 2015, 31(12): 1941-1960. DOI: 10.3969/j.issn.1001-5256.2015.12.002.
|
[6] |
WU Y, LIU Y, LU J, et al. Durability of interferon-induced hepatitis B surface antigen seroclearance[J]. Clin Gastroenterol Hepatol, 2020, 18(2): 514-516.e2. DOI: 10.1016/j.cgh.2019.04.020.
|
[7] |
MARCELIN P, FLISIAK R, TRINH H, et al. Long term treatment with tenofbvir disoproxil fumarate for chronic hepatitis B infection is safe and well tolerated and associated with durable virologic response with no detectable resistance: 8 year results from two phase 3 trials[J]. Hepatol, 2014, 60: 313a-314a. DOI: 10.1002/hep.27059.
|
[8] |
LAMPERTICO P, VIGANÒ M, DI COSTANZO GG, et al. Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B[J]. Gut, 2013, 62(2): 290-298. DOI: 10.1136/gutjnl-2011-301430.
|
[9] |
CHELBI-ALIX MK, WIETZERBIN J. Interferon, a growing cytokine family: 50 years of interferon research[J]. Biochimie, 2007, 89(6-7): 713-718. DOI: 10.1016/j.biochi.2007.05.001.
|
[10] |
ZHANG S, SUN J, XING HC. Progress on clinical cure of chronic hepatitis B[J/CD]. Chin J Liver Dis (Electronic Version), 2018, 10(4): 54-58. DOI: 10.3969/j.issn.1674-7380.2018.04.009.
张珊, 孙静, 邢卉春. 慢性乙型肝炎临床治愈研究进展[J/CD]. 中国肝脏病杂志(电子版), 2018, 10(4): 54-58. DOI: 10.3969/j.issn.1674-7380.2018.04.009.
|
[11] |
HAGIWARA S, NISHIDA N, KUDO M. Antiviral therapy for chronic hepatitis B: Combination of nucleoside analogs and interferon[J]. World J Hepatol, 2015, 7(23): 2427-2431. DOI: 10.4254/wjh.v7.i23.2427.
|
[12] |
TAN AT, HOANG LT, CHIN D, et al. Reduction of HBV replication prolongs the early immunological response to IFNα therapy[J]. J Hepatol, 2014, 60(1): 54-61. DOI: 10.1016/j.jhep.2013.08.020.
|
[13] |
NING Q, HAN M, SUN Y, et al. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomised open-label trial (OSST trial)[J]. J Hepatol, 2014, 61(4): 777-784. DOI: 10.1016/j.jhep.2014.05.044.
|
[14] |
HU P, SHANG J, ZHANG WH, et al. HBsAg loss with Pegylated-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)ide analog: New Switch study[J]. Chin J Hepatol, 2018, 26(10): 756-764. DOI: 10.3760/cma.j.issn.1007-3418.2018.10.005.
胡鹏, 尚佳, 张文宏, 等. 核苷(酸)类似物治疗部分应答的乙型肝炎患者通过聚乙二醇干扰素α-2a治疗获得HBsAg消失: New Switch研究[J]. 中华肝脏病杂志, 2018, 26(10): 756-764. DOI: 10.3760/cma.j.issn.1007-3418.2018.10.005.
|
[15] |
LIN B, HA NB, LIU A, et al. Low incidence of hepatitis B e antigen seroconversion in patients treated with oral nucleos(t)ides in routine practice[J]. J Gastroenterol Hepatol, 2013, 28(5): 855-860. DOI: 10.1111/jgh.12108.
|
[16] |
ZOUTENDIJK R, HANSEN BE, van VUUREN AJ, et al. Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss[J]. J Infect Dis, 2011, 204(3): 415-418. DOI: 10.1093/infdis/jir282.
|
[17] |
CHEN XY, LIU YL. How patients with hepatitis B get really recovered[J]. J Prac Hepatol, 2016, 19(3): 257-260. DOI: 10.3969/j.issn.1672-5069.2016.03.001.
陈新月, 刘雅立. 慢性乙型肝炎患者如何获得临床治愈[J]. 实用肝脏病杂志, 2016, 19(3): 257-260. DOI: 10.3969/j.issn.1672-5069.2016.03.001.
|